Joshua Jennings
Stock Analyst
(3.65)
# 3,339
Out of 4,648 analysts
62
Total ratings
49.12%
Success rate
7.8%
Average return
Main Sectors:
Stocks Rated by Joshua Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BSX Boston Scientific | Maintains: Buy | $86 → $100 | $84.72 | +18.04% | 6 | Oct 21, 2024 | |
| HUMA Humacyte | Reiterates: Buy | $10 | $5.07 | +97.24% | 2 | Oct 18, 2024 | |
| ALUR Allurion Technologies | Initiates: Buy | $2 | $0.69 | +188.89% | 1 | Oct 2, 2024 | |
| PRCT PROCEPT BioRobotics | Maintains: Buy | $75 → $99 | $97.07 | +1.99% | 3 | Sep 16, 2024 | |
| ZBH Zimmer Biomet Holdings | Maintains: Hold | $143 → $119 | $108.41 | +9.77% | 1 | Sep 6, 2024 | |
| VCEL Vericel | Maintains: Buy | $55 → $60 | $44.37 | +35.23% | 2 | Aug 27, 2024 | |
| AIG American International Group | Maintains: Hold | $83 → $80 | $76.33 | +4.81% | 1 | Aug 13, 2024 | |
| OM Outset Medical | Maintains: Buy | $9 → $3 | $0.62 | +383.56% | 3 | Aug 8, 2024 | |
| EW Edwards Lifesciences | Downgrades: Hold | $100 → $70 | $66.47 | +5.31% | 1 | Jul 25, 2024 | |
| JNJ Johnson & Johnson | Maintains: Buy | $195 → $185 | $158.24 | +16.91% | 1 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $84.97 | +105.96% | 8 | Jun 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $40 | $35.80 | +11.73% | 4 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $365 → $400 | $366.90 | +9.02% | 2 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $50 → $60 | $46.76 | +28.31% | 4 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $52 → $34 | $32.85 | +3.50% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $14 → $18 | $8.20 | +119.51% | 3 | May 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $69.70 | +79.34% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $25 | $18.34 | +36.31% | 1 | Dec 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 | $117.65 | +10.50% | 9 | Dec 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $5 | $1.94 | +157.73% | 1 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $125 → $117 | $89.31 | +31.00% | 3 | May 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $450 | $8.06 | +5,483.13% | 1 | Dec 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $12 | $8.36 | +43.54% | 1 | Sep 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $306 → $275 | $234.33 | +17.36% | 1 | Feb 7, 2020 |
Boston Scientific
Oct 21, 2024
Maintains: Buy
Price Target: $86 → $100
Current: $84.72
Upside: +18.04%
Humacyte
Oct 18, 2024
Reiterates: Buy
Price Target: $10
Current: $5.07
Upside: +97.24%
Allurion Technologies
Oct 2, 2024
Initiates: Buy
Price Target: $2
Current: $0.69
Upside: +188.89%
PROCEPT BioRobotics
Sep 16, 2024
Maintains: Buy
Price Target: $75 → $99
Current: $97.07
Upside: +1.99%
Zimmer Biomet Holdings
Sep 6, 2024
Maintains: Hold
Price Target: $143 → $119
Current: $108.41
Upside: +9.77%
Vericel
Aug 27, 2024
Maintains: Buy
Price Target: $55 → $60
Current: $44.37
Upside: +35.23%
American International Group
Aug 13, 2024
Maintains: Hold
Price Target: $83 → $80
Current: $76.33
Upside: +4.81%
Outset Medical
Aug 8, 2024
Maintains: Buy
Price Target: $9 → $3
Current: $0.62
Upside: +383.56%
Edwards Lifesciences
Jul 25, 2024
Downgrades: Hold
Price Target: $100 → $70
Current: $66.47
Upside: +5.31%
Johnson & Johnson
Jul 18, 2024
Maintains: Buy
Price Target: $195 → $185
Current: $158.24
Upside: +16.91%
Jun 7, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $84.97
Upside: +105.96%
May 10, 2024
Downgrades: Hold
Price Target: $40
Current: $35.80
Upside: +11.73%
Apr 11, 2024
Maintains: Buy
Price Target: $365 → $400
Current: $366.90
Upside: +9.02%
Mar 12, 2024
Maintains: Outperform
Price Target: $50 → $60
Current: $46.76
Upside: +28.31%
Aug 4, 2023
Maintains: Outperform
Price Target: $52 → $34
Current: $32.85
Upside: +3.50%
May 11, 2023
Maintains: Outperform
Price Target: $14 → $18
Current: $8.20
Upside: +119.51%
Feb 10, 2023
Maintains: Outperform
Price Target: $114 → $125
Current: $69.70
Upside: +79.34%
Dec 30, 2022
Maintains: Outperform
Price Target: $6 → $25
Current: $18.34
Upside: +36.31%
Dec 13, 2022
Maintains: Outperform
Price Target: $130
Current: $117.65
Upside: +10.50%
Nov 11, 2022
Maintains: Outperform
Price Target: $7 → $5
Current: $1.94
Upside: +157.73%
May 27, 2022
Maintains: Outperform
Price Target: $125 → $117
Current: $89.31
Upside: +31.00%
Dec 7, 2021
Initiates: Outperform
Price Target: $450
Current: $8.06
Upside: +5,483.13%
Sep 3, 2020
Initiates: Outperform
Price Target: $12
Current: $8.36
Upside: +43.54%
Feb 7, 2020
Downgrades: Market Perform
Price Target: $306 → $275
Current: $234.33
Upside: +17.36%